The assessment of renal function during the therapy of arterial hypertension with azilsartan medoxomil in patients with obesity or overweight and concomitant metabolic disorders
- Authors: Nevzorova V.A.1, Petrichko T.A.2, Chazova I.E.3, Zhernakova J.V.3
-
Affiliations:
- Pacific State Medical University
- Postgraduate Institute for Public Health Workers
- National Medical Research Center of Cardiology
- Issue: Vol 93, No 12 (2021)
- Pages: 1510-1515
- Section: Original articles
- URL: https://journals.rcsi.science/0040-3660/article/view/96476
- DOI: https://doi.org/10.26442/00403660.2021.12.201270
- ID: 96476
Cite item
Full Text
Abstract
Aim. To assess the influence of the therapy of arterial hypertension with azilsartan medoxomil on the renal function in overweight or obese patients with concomitant metabolic disorders.
Materials and methods. An international multicenter observational nonintervention prospective study included 1945 patients, taking azilsartan medoxomil in accordance with approved prescribing information. The observation period reached 6 months.
Results. In patients with an initial glomerular filtration rate (GFR)<60 ml/min/1.73 m2 or ≥60 ml/min/1.73 m2 mean change in systolic blood pressure after 6 months of therapy reached -32.5±11.1 and -30.4±13.6 mmHg, correspondingly, while the change in diastolic blood pressure was -13.7±8.8 and -14.2±9.4 mmHg, respectively. No decrease in renal function was observed. Moreover, in patients with an initial GFR<60 ml/min/1.73 m2 GFR increased significantly (p<0.001).
Conclusion. Azilsartan medoxomil, prescribed as monotherapy or in free combinations, provided an effective control of blood pressure in patients with arterial hypertension with both normal or moderately reduced and initially significantly reduced renal function. High efficacy and acceptability of the drug was associated with a beneficial effect on renal function, which allows to consider azilsartan medoxomil as the drug of choice for the treatment of hypertension in patients with concomitant metabolic disorders.
Full Text
##article.viewOnOriginalSite##About the authors
Vera A. Nevzorova
Pacific State Medical University
Email: juli001@mail.ru
ORCID iD: 0000-0002-0117-0349
д-р мед. наук, проф., дир. Института терапии и инструментальной диагностики
Russian Federation, VladivistokTatiana A. Petrichko
Postgraduate Institute for Public Health Workers
Email: juli001@mail.ru
ORCID iD: 0000-0003-1770-3370
д-р мед. наук, зав. каф. терапии и профилактической медицины
Russian Federation, KhabarovskIrina E. Chazova
National Medical Research Center of Cardiology
Email: juli001@mail.ru
ORCID iD: 0000-0002-9822-4357
акад. РАН д-р мед. наук, проф., зам. дир. по научно-экспертной работе
Russian Federation, MoscowJuliya V. Zhernakova
National Medical Research Center of Cardiology
Author for correspondence.
Email: juli001@mail.ru
ORCID iD: 0000-0001-7895-9068
д-р мед. наук, ученый секретарь Института клинической кардиологии им. А.Л. Мясникова
Russian Federation, MoscowReferences
- Clase CM, Garg AX, Kiberd BA. Prevalence of low glomerular filtration in nondiabetic Americans: Third national Health and Nutrition Examination Survey (NHANES III). J Am Soc Nephrol. 2002;13(5):1338-49. doi: 10.1097/01.asn.0000013291.78621.26
- Российское медицинское общество по артериальной гипертонии. Рекомендации по ведению больных артериальной гипертонией с метаболическими нарушениями и сахарным диабетом 2-го типа. Системные гипертензии. 2020;17(1):7-45 [Russian society of hypertension. Guidelines on treatment of patients with arterial hypertension comorbid with metabolic disorders and diabetes mellitus type 2. Systemic Hypertension. 2020;17(1):7-45 (in Russian)]. doi: 10.26442/2075082X.2020.1.200051
- Williams B, Mancia G, Spiering W, et al.; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-104. doi: 10.1093/eurheartj/ehy339
- Чазова И.Е., Жернакова Ю.В. от имени экспертов. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии. 2019;16(1):6-31 [Chazova IE, Zhernakova YuV on behalf of the experts. Clinical guidelines. Diagnosis and treatment of arterial hypertension. Systemic Hypertension. 2019;16(1):6-31 (in Russian)]. doi: 10.26442/2075082X.2019.1.190179
- Bönner G, Bakris GL, Sica D, et al. Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril. J Hum Hypertens. 2013;27(8):479-86. doi: 10.1038/jhh.2013.6
- White WB, Cuadra RH, Lloyd E, et al. Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes. J Hypertens. 2016;34(4):788-97. doi: 10.1097/HJH.0000000000000839
- White WB, Weber MA, Sica D, et al. Effects of the angiotensin recep tor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension. 2011;57(3):413-20. doi: 10.1161/HYPERTENSIONAHA.110.163402
- Bakris GL, Sica D, Weber M, et al. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens (Greenwich). 2011;13(2):81-8. doi: 10.1111/j.1751-7176.2010.00425.x
- Ferdinand KC, Bakris GL, Cushman WC, et al. Comparison of effectiveness of azilsartan medoxomil and olmesartan in blacks versus whites with systemic hypertension. Am J Cardiol. 2018;122(9):1496-505. doi: 10.1016/j.amjcard.2018.07.022
- Rakugi H, Enya K, Sugiura K, Ikeda Y. Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I–II essential hypertension: a randomized, double-blind clinical study. Hypertens Res. 2012;35(5):552-8. doi: 10.1038/hr.2012.8
- Sica D, White WB, Weber MA, et al. Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich). 2011;13(7):467-72. doi: 10.1111/j.1751-7176.2011.00482.x
- Недогода С.В., Чумачек Е.В., Цома В.В., и др. Возможности азилсартана в коррекции инсулинорезистентности и уровня адипокинов при артериальной гипертензии в сравнении с другими сартанами. Российский кардиологический журнал. 2019;1:70-9 [Nedogoda SV, Chumachek EV, Tsoma VV, et al. Effectiveness of in insulin resistance correction and the adipokines level reduction in patients with arterial hypertension in comparison with other ARBs. Russian journal of cardiology. 2019;1:70-9 (in Russian)]. doi: 10.15829/1560-4071-2019-1-70-79
- Takagi H, Mizuno Y, Niwa M, et al.; ALICE (All-Literature Investigation of Cardiovascular Evidence) Group. A meta-analysis of randomized controlled trials of azilsartan therapy for blood pressure reduction. Hypertens Res. 2014;37(5):432-7. doi: 10.1038/hr.2013.142
- Gitt AK, Bramlage P, Potthoff SA, et al.; EARLY Registry Group. Azilsartan compared to ACE inhibitors in anti-hypertensive therapy: one-year outcomes of the observational EARLY registry. BMC Cardiovasc Disord. 2016;16(1):56. doi: 10.1186/s12872-016-0222-6
- Жернакова Ю.В., Чазова И.Е. Возможности нового блокатора рецепторов к ангиотензину в улучшении контроля артериальной гипертонии. Международное многоцентровое наблюдательное неинтервенционное проспективное исследование применения азилсартана медоксомила. Системные гипертензии. 2018;13(3):6-12 [Zhernakova YuV, Chazova IE. The possibility of a new receptor blocker to angiotensin in improving control of hypertension. Non-intervention international multicenter observational prospective study of the use azilsartan medoxomil in patients with arterial hypertension and overweight or obesity in the Russian Federation and the Republic of Kazakhstan. Systemic Hypertension. 2016;13(3):6-12 (in Russian)].
- Чазова И.Е., Ощепкова Е.В., Жернакова Ю.В. Диагностика и лечение артериальной гипертонии. Евразийский кардиологический журнал. 2015;2:3-30 [Chazova IE, Oshepkova EV, Zhernakova YuV. Diagnostics and treatment of arterial hypertension. Eurasian heart journal. 2015;2:3-30 (in Russian)].
- Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-12. doi: 10.7326/0003-4819-150-9-200905050-00006
- Iwai M, Chen R, Imura Y, Horiuchi M. TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation. Am J Hypertens. 2007;20(5):579-86. doi: 10.1016/j.amjhyper.2006.12.010
- Петросов С.Л., Фомин В.В. Опыт применения азилсартана медоксомила (Эдарби) у пациентов с артериальной гипертензией в амбулаторной практике. Фарматека. 2015;9:51-5 [Petrosov SL, Fomin VV. Opyt primeneniia azilsartana medoksomila (Edarbi) u patsientov s arterial'noi gipertenziei v ambulatornoi praktike. Pharmateca. 2015;9:51-5 (in Russian)].
- Takami T, Okada S, Saito Y, et al. Effects of Olmesartan and Azilsartan on Albuminuria and the Intrarenal Renin-Angiotensin System. World J Res Rev. 2018;6(1):7-10.
- Ukimura A, Matsuda H, Yamauchi Y, et al. Azilsartan is more effective as compared to olmesartan in hemodialysis patients with uncontrolled hypertension. J Nephrol Ther. 2014;5(1). doi: 10.4172/2161-0959.1000193
- Kusuyama T, Ogata H, Takeshita H, et al. Effects of azilsartan compared to other angiotensin receptor blockers on left ventricular hypertrophy and the sympathetic nervous system in hemodialysis patients: comparison of azilsartan with other ARBs. Ther Apher Dial. 2014;18(5):398-403. doi: 10.1111/1744-9987.12168